供者来源与移植后环磷酰胺对GATA2缺陷患者异基因造血干细胞移植结局的影响
接受PT/Cy预防的MRD和URD受者中无人发生III-IV级aGVHD,而接受Tacrolimus/Methotrexate者该发生率为32%。
要点
- 含白消安方案HSCT可逆转GATA2缺陷的血液学表型。
- PT/Cy较Tacrolimus/Methotrexate降低III-IV级aGVHD风险。
- PT/Cy同时降低aGVHD与cGVHD风险。
核心结论
- 含白消安方案的HSCT可逆转GATA2缺陷的血液学疾病表型。
- 使用PT/Cy降低了aGVHD和cGVHD的风险。
研究设计与样本
- 报告2013至2020年间在美国国立卫生研究院接受HSCT的59例GATA2突变患者。
- 主要终点为植入和临床表型逆转,次要终点为OS、EFS及急慢性GVHD发生率。
主要发现
- 接受Tacrolimus/Methotrexate预防的MRD和URD受者III-IV级aGVHD发生率为32%。
- 接受PT/Cy的MRD和URD受者中无人发生III-IV级aGVHD。
- 6%的HRD受者发生III-IV级aGVHD。
临床怎么用
- GATA2缺陷患者可考虑含白消安方案的HSCT以逆转血液学表型。
- PT/Cy可用于降低MRD和URD移植后aGVHD与cGVHD风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
GATA2 deficiency was described in 2011, and shortly thereafter allogeneic hematopoietic stem cell transplantation (HSCT) was shown to reverse the hematologic disease phenotype. However, there remain major unanswered questions regarding the type of conditioning regimen, type of donors, and graft-versus-host disease (GVHD) prophylaxis. We report 59 patients with GATA2 mutations undergoing HSCT at National Institutes of Health between 2013 and 2020. Primary endpoints were engraftment, reverse of the clinical phenotype, secondary endpoints were overall survival (OS), event-free survival (EFS), and the incidence of acute and chronic GVHD. The OS and EFS at 4 years were 85·1% and 82·1% respectively. Ninety-six percent of surviving patients had reversal of the hematologic disease phenotype by one-year post-transplant. Incidence of grade III-IV aGVHD in matched related donor (MRD) and matched unrelated donor recipients (URD) patients receiving Tacrolimus/Methotrexate for GVHD prophylaxis was 32%. In contrast, in the MRD and URD who received post-transplant cyclophosphamide (PT/Cy), no patient developed grade III-IV aGVHD. Six percent of haploidentical related donor (HRD) recipients developed grade III-IV aGVHD. In summary, a busulfan-based HSCT regimen in GATA2 deficiency reverses the hematologic disease phenotype, and the use of PT/Cy reduced the risk of both aGVHD and cGVHD.
引用
- Nichols-Vinueza DX, Parta M, Shah NN, et al. Donor source and post-transplantation cyclophosphamide influence outcome in allogeneic stem cell transplantation for GATA2 deficiency. Br J Haematol. 2021. PMID: 34580862. doi:10.1111/bjh.17840
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。